| Name | Title | Contact Details |
|---|
Senomyx is using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients. These include modifiers of Sweet and Salt flavors as well as Savory Flavors, Bitter Blockers, and Cooling Agents. The Company is also engaged in an effort to discover and develop natural high-potency sweeteners. Under its direct sales program, Senomyx is beginning to sell certain of its Complimyx brand flavor ingredients, Sweetmyx, Savorymyx, and Bittermyx, to flavor companies for re-sale to their food and beverage company customers. In addition, Senomyx has collaborative agreements with global food, beverage, and ingredient supply companies, some of which are currently marketing products that contain Senomyx's flavor ingredients.
On Belay Health Solutions is a company that supports independent primary care physicians in their quest to access meaningful value-based contracts and provides the clinical support necessary to succeed and maintain their independence.
lifeIMAGE is an interoperable medical image sharing network that helps healthcare providers access their patients` imaging records, regardless of where exams are performed or stored. It has been adopted by more than 120 multi-site health systems across the country to improve care coordination for patient consultations, referrals and transfers. This enables providers to improve the quality and timeliness of care, expand referral business, and eliminate wasteful spending.
Medocity is a leading healthcare tech and services company specializing in digital care solutions to deliver optimized, continuous care between visits.
Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.